Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
UNIVERSITY COLLEGE DUBLIN is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, which indicates a lack of concentration in the prosecution process. Each examiner handles a single application, requiring the legal team to adapt to 3 different sets of examiner preferences and styles.
The 3 pending actions are further divided across 3 distinct art units. This distribution means that every pending action is being evaluated by a different technical group within the patent office. Practitioners must be prepared to address the specific examination standards of different administrative groups within the Biotechnology & Pharmaceuticals field.
HIRAKIS, SOPHIA P is identified as the busiest examiner for this portfolio, currently holding 1 pending office action. Because the busiest examiner only manages 1 of the 3 total actions, there is no primary point of contact for the portfolio. Success in these 3 pending office actions will require a decentralized strategy that addresses the unique technical and procedural demands of each individual examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCGRATH, ERIN E | 1 | 60.1% | +28.6% |
| MOAZZAMI, NAGHMEH NINA | 1 | 72.0% | +49.3% |
| HAYES, JONATHAN EDWARD | 1 | 36.4% | +20.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18850158 | AN ENDOVASCULAR OCCLUSION DEVICE | MCGRATH, ERIN E | — |
| 18041352 | BETA-1,4 GALACTOSYLATION OF PROTEINS | MOAZZAMI, NAGHMEH NINA | — |
| 17598497 | CONFIGURATIONAL ENERGY CALCULATION AND CRYSTAL STRUCTURE PREDICTION | HAYES, JONATHAN EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18850158 | AN ENDOVASCULAR OCCLUSION DEVICE | MCGRATH, ERIN E | — |
| 18041352 | BETA-1,4 GALACTOSYLATION OF PROTEINS | MOAZZAMI, NAGHMEH NINA | — |
| 17598497 | CONFIGURATIONAL ENERGY CALCULATION AND CRYSTAL STRUCTURE PREDICTION | HAYES, JONATHAN EDWARD | — |
| Art Unit | Apps |
|---|---|
| 3771 | 1 |
| 1652 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850158 | AN ENDOVASCULAR OCCLUSION DEVICE | MCGRATH, ERIN E | 3771 | §102§103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18041352 | BETA-1,4 GALACTOSYLATION OF PROTEINS | MOAZZAMI, NAGHMEH NINA | 1652 | §102§112Other | Final Rejection | — | Pending | Feb 10, 2023 |
| 17598497 | CONFIGURATIONAL ENERGY CALCULATION AND CRYSTAL STRUCTURE PREDICTION | HAYES, JONATHAN EDWARD | 1685 | §101§102§103 | Final Rejection | — | Pending | Sep 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial